Welcome to CienciaPR, an expert and resource network for all who are interested in science and Puerto Rico.
Mi nombre es Yarelis Díaz Rohena. Estudio en la Universidad de Puerto Rico, Recinto de Río Piedras y completaré mi bachillerato en el Programa Interdisciplinario de la Facultad de Ciencias Naturales en junio de 2018. Soy parte del equipo de investigadores subgraduados en el Laboratorio de Proteómica Cuantitativa del Centro Comprensivo de Cáncer (UPR-RCM) desde julio de 2016. Comenzaré el Doctorado en Farmacia (PharmD) en agosto de 2018 y aspiro a especializarme en Farmacia Oncológica.
My name is Yarelis Díaz Rohena. I’m a student at the University of Puerto Rico, Río Piedras Campus, about to complete the Bachelor’s Degree in the Faculty of Natural Sciences Interdisciplinary Studies Program in June 2018. I’ve been part of the team of undergraduate researchers at the Comprehensive Cancer Center’s Quantitative Proteomics Laboratory since July 2016. I will begin the PharmD Program in August 2018, and aim to specialize in Oncology Pharmacy.
Díaz Y; Miranda E; Fred RM; Mesa R, Camafeita E; Vázquez J; Cerrudo IJ; Vilá LM; Serrano H. Abatacept alters plasma proteome in rheumatism patients [abstract]. In: RCMI Translational Science 2017 Conference; 2017 Oct 28-Nov 1; Washington, D.C. Abstract no. 05.05.003.
PURPOSE: Abatacept is a biological drug designed to reduce the symptoms and signs of rheumatoid arthritis (RA) in adult patients and juvenile idiopathic arthritis. To this date, protein changes and pathways altered by consumption of this drug have not been well characterized. In this regard, our goal was to determine the changes in plasma proteins from RA patients treated with abatacept using Quantitative Proteomics (QP). METHODS: Six adults (>21year old) with RA (per 1987 ACR classification criteria) were evaluated before and after 3 months of abatacept administration. Blood samples were collected for proteomic analysis. Plasma samples were depleted from albumin and IgG and processed by multiplexed. QP analysis was assessed after tryptic digestion and isobaric peptide labeling (iTRAQ-4-plex) using liquid chromatography coupled to mass spectrometry (LC-MS/MS-Q-ExactiveTM). RESULTS: 576 proteins (false-discovery rate< 0.05) were identified and quantified with more than 1 peptide. QP data revealed that levels of 42 proteins were significantly altered as a result of abatacept treatment. Among the observed changes, we found that Serum amyloid A-1 (P0DJ18) protein expression was down-regulated in 50% of the patients, consistent with treatment success. Inflammatory proteins were categorized in 9 groups: C-reactive protein-(1%), rheumatoid factor-(8%), serum protein A from amyloid-(7%), haptoglobin-(3%), fibrinogen-(5%), complement factors-(39%), ceruloplasmin-(3%), acid glycoprotein-1-(17%) and llpha-1 antitrypsin-antichemotrypsin-(17%). CONCLUSIONS: Our results demonstrate that abatacept induces dynamic changes in a wide spectrum of inflammatory-related proteins in plasma from RA patients. This information could lead to the identification of potential biomarkers to determine therapy effectiveness and patient’s outcome.
Find resources related to scientific publications
See our funding feeds from the NIH and the NSF
See our jobs feeds from various sources.